Kapil N. Bhalla, M.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Kapil N. Bhalla
Dr. Bhalla is a nationally and internationally recognized physician scientist for his original basic/translational research findings that have led to the clinical testing of novel targeted agents or combinations for the therapy of leukemia and myeloproliferative neoplasms. Dr. Bhalla currently serves as a Professor and Kelcie Kana Research Chair in the Leukemia Department of MD Anderson Cancer Center, Houston TX. Until 2014, he was a Full Member and the Scientific and Medical Director of the Cockrell Center for Advanced Therapeutics and Co-Director of the Phase Clinical Research Unit of the Houston Methodist Research Institute. In the past, Dr. Bhalla served as the Deputy Director of University of Kansas Cancer Center and Founding Director of the Medical College of Georgia Cancer Center. A graduate of the University of Delhi’s Maulana Azad Medical College in India, he completed internships in Pathology and Internal Medicine and a residency in Internal Medicine in the US. Following a Post-doctoral Fellowship in Hematology and Oncology at Columbia University College of Physicians and Surgeons in New York, he served as a Professor on the faculty of the Medical University of South Carolina, Emory University, University of Miami and University of South Florida. He is Board-certified in Internal Medicine, Hematology and Medical Oncology. He is a past recipient of the American Cancer Society’s Career Development Award, the Leukemia & Lymphoma Society of America’s Fellow and Scholar Awards. He also served as the Eminent Scholar of Georgia Research Alliance, Distinguished Cancer Scientist of Georgia Cancer Coalition and Kansas Bioscience Authority Eminent Scholar. He has been formerly a member of Experimental Therapeutics II and Basic Mechanisms of Cancer Therapy, and Chairperson of the Developmental Therapeutics Study Section. He is the author of more than 220 scholarly articles on cancer research. Dr. Bhalla’s current basic and translational research is supported by multiple NCI RO1 grants of which he is the principal investigator. His research is focused on cancer epigenetics, signaling and chaperone biology, with the goal to pre-clinically develop novel targeted therapies of leukemia and lymphoma. This research involves elucidating the biology of potential therapeutic targets and mechanisms of activity and resistance to the novel anti-cancer agents that engage the targets and the cancer-specific dependencies. These targets include mutant signaling proteins, molecular chaperones and epigenetic modifiers (writers, eraser and reader proteins). Specifically, the research focus is on mutant NPM1, FLT3 and epigenetic targets such as KDM1A, BET proteins and polycomb complex 2. This research also includes the elucidation of the predictive biomarkers of clinical efficacy of the novel anticancer agents or their combinations.
Present Title & Affiliation
Primary Appointment
Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Kelcie Kana Research Chair, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1976 | Maulana Azad Medical College, University of Delhi, Delhi, IN, MD |
Postgraduate Training
| 1980-1983 | Fellowship, Hematology/Oncology, Columbia University College of Physicians & Surgeons, New York, New York |
| 1978-1980 | Residency, Internal Medicine, St. Michael's Medical Center, Newark, New Jersey |
| 1977-1978 | Internship, Internal Medicine, St. Michael's Medical Center, Newark, New Jersey |
| 1976-1977 | Internship, Pathology, St. Michael's Medical Center, Newark, New Jersey |
Licenses & Certifications
| 2017 | Not specified |
| 2011 | Not specified |
| 1999 | Not specified |
| 1995 | Not specified |
| 1989 | Not specified |
| 1983 | Diplomate, American Board of Internal Medicine, Subspecialty of Medical Oncology |
| 1982 | Diplomate, American Board of Internal Medicine, Subspecialty of Hematology |
| 1980 | Not specified |
| 1979 | Diplomate, American Board of Internal Medicine |
| 1977 | Not specified |
Experience & Service
Faculty Academic Appointments
Schutte/Speas Endowed Chair in Hematological Malignancies, The University of Kansas Cancer Center, Kansas City, KS, 2010 - 2013
Professor, Department of School of Medicine, Medical College of Georgia (MCG), Augusta, GA, 2006 - 2010
Cecil F. Whitaker Eminent Scholar in Cancer, Medical College of Georgia (MCG), Augusta, GA, 2006 - 2010
Professor, Department of Interdisciplinary Oncology, Biochemistry & Molecular Biology Pharmacology & Therapeutics, Internal Medicine, University of South Florida, Tampa, FL, 2000 - 2006
Sylvester Distinguished Professor of Oncology, Department of University of Miami, School of Medicine, Sylvester Comprehensive Cancer Center Clinical and Translational Research, Miami, FL, 1999 - 2000
Professor, Department of Medicine and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 1995 - 1998
Professor, Department of Medicine, Medical University of South Carolina, Charleston, SC, 1994 - 1995
Associate Professor, Department of Medicine, Medical University of South Carolina, Charleston, SC, 1989 - 1994
Assistant Professor, Department of Medical Oncology and Hematology, Columbia University College of Physicians & Surgeons, New York, NY, 1985 - 1989
Instructor, Department of Medical Oncology and Hematology, Columbia University College of Physicians & Surgeons, New York, NY, 1983 - 1984
Administrative Appointments/Responsibilities
Director, Department of Cockrell Center for Advanced Therapeutics, Houston Methodist Research Institute, Houston, TX, 2013 - 2014
Deputy Director, The University of Kansas Cancer Center, Kansas City, KS, 2010 - 2013
Chief of Personalized Cancer, The University of Kansas Cancer Center, Kansas City, KS, 2010 - 2013
Founding Director, MCG Cancer Center Georgia Research Alliance, Medical College of Georgia (MCG), Augusta, GA, 2006 - 2010
Associate Director, Department of University of Miami, School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, 1999 - 2000
Chief, Department of University of Miami, School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, 1999 - 2000
Associate Director, Translational Sciences, Emory University School of Medicine, Atlanta, GA, 1996 - 1998
Honors & Awards
| 2021 | Waun Ki Hong Award for Excellence in Team Science, MD Anderson Cancer Center |
| 2011 - 2013 | Member Scientific Program Committee, Track Leader, Tumor Biology, American Society of Clinical Oncology |
| 2010 - 2013 | Eminent Scholar, Kansas Bioscience Authority |
| 2008 - 2010 | Distinguished Cancer Scholar, Georgia Cancer Coalition |
| 2007 - 2008 | Chair, Lymphoid Neoplasia Committee, American Society of Hematology |
| 2006 - 2010 | Cecil F. Whitaker Eminent Scholar in Cancer, Georgia Research Alliance |
| 2006 - 2007 | Chair, Neoplasia Committee, American Society of Hematology |
| 2005 - 2006 | Member Scientific Program Committee, Developmental Therapeutics, American Society of Clinical Oncology |
| 2004 - 2005 | Member Scientific Program Committee, Breast Track, American Society of Clinical Oncology |
| 1993 - 1994 | Health Science Foundation Developing Scholar Award, Medical University of South Carolina, Charleston, SC |
| 1992 - 1997 | Leukemia Society of America Scholar Award, Leukemia Society of America |
| 1985 - 1988 | American Cancer Society Clinical Oncology Career Development Award, American Cancer Society |
| 1983 - 1985 | Leukemia Society of America Fellow Award, Leukemia Society of America |
| 1969 | National Science Talent Search Scholarship, India |
Professional Memberships
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Role of targeting ATPases BRG1/BRM in therapy of AML |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | R01CA291918 |
| Date: | 2024 - 2029 |
| Title: | Developing novel targeted therapies for Advanced Myeloproliferative Neoplasms |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | CA288304-01 |
| Date: | 2023 - 2024 |
| Title: | Pre-clinical Laboratory Studies with DSP-5336 |
| Funding Source: | Sumitomo Pharma Oncology, Inc |
| Role: | PI |
| ID: | RCTS#62750 |
| Date: | 2023 - 2030 |
| Title: | Elucidating and targeting epigenetic mechanisms and dysregulated transcriptome-based vulnerabilities to eradicate minimal residual disease Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT13751741 |
| Date: | 2023 - 2028 |
| Title: | Biology and efficacy of Menin Inhibitors in AML therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2023 - 2028 |
| Title: | Biology and efficacy of Menin Inhibitors in AML therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA272870 |
| Date: | 2023 - 2026 |
| Title: | Developing novel Menin Inhibitor-based combinations for therapy of AML with MLL1 rearrangement or mutant NPM1 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | CA276036 |
| Date: | 2023 - 2024 |
| Title: | Biology and targeting of chromatin remodeler ATPases in AML |
| Funding Source: | MDACC |
| Role: | PI |
| ID: | Institutional Research Grant (IRG) |
| Date: | 2022 - 2025 |
| Title: | Developing novel targeted therapies of Advanced Myeloproliferative Neoplasms |
| Funding Source: | MDACC |
| Role: | Co-PI |
| ID: | MDACC MRP |
| Date: | 2022 - 2025 |
| Title: | Developing novel Menin Inhibitor-based combinations for therapy of AML with MLL1 rearrangement or mutant NPM1 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01-CA276036 |
| Date: | 2022 - Present |
| Title: | Preclinical studies of efficacy of tasquinimod (TM) in models of myelofibrosis and post-MPN sAML |
| Funding Source: | Active Biotech Research AB |
| Role: | PI |
| ID: | 00060574 |
| Date: | 2021 - 2023 |
| Title: | Preclinical Studies with FHD286 in AML Cell Models |
| Funding Source: | Foghorn Therapeutics |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Pre-clinical efficacy of BTK chimeric targeting molecule (CTM) NX-2127 and BTK degrader NX-5948 against MCL and RT-DLBCL cells |
| Funding Source: | Nurix Therapeutics, Inc |
| Role: | PI |
| ID: | 60020 |
| Date: | 2021 - 2025 |
| Title: | Novel combination therapy for AML expressing mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01 CA262636 |
| Date: | 2020 - 2025 |
| Title: | Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA240839-01A1 |
| Date: | 2020 - 2025 |
| Title: | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01-CA255721 |
| Date: | 2020 - 2025 |
| Title: | Targeting Dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01-CA233457 |
| Date: | 2019 - 2024 |
| Title: | Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA233457-01 |
| Date: | 2019 - 2024 |
| Title: | Persistent DNA hyper-methylation of the IFN-γ signaling pathway during tuberculosis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | K23AI141681A |
| Date: | 2019 - 2020 |
| Title: | Targeted Therapy for AML expressing somatic or germline mutant RUNX1 |
| Funding Source: | Leukemia Texas |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | Therapy for AML expressing somatic or germline mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 |
| Date: | 2019 - 2021 |
| Title: | Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-PI |
| Date: | 2018 - 2023 |
| Title: | Targeted Therapy for AML expressing somatic or germline mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA228179-01A1 |
| Date: | 2018 - 2025 |
| Title: | Elucidating and targeting epigenetic mechanisms and dysregulated transcriptome-based vulnerabilities in AML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R35 CA232127-01 |
| Date: | 2018 - 2023 |
| Title: | Therapeutic targeting of dysregulated epigenome in Post-Myeloproliferative Neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA220930 |
| Date: | 2018 - 2023 |
| Title: | Targeted Therapy for AML expressing somatic or germline mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA228179 |
| Date: | 2018 - 2023 |
| Title: | Novel Therapy for Post-Myeloproliferative Neoplasm (MPN) sAML” |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP180430 |
| Date: | 2018 - 2023 |
| Title: | Targeted Epigenetic Drugs as Adjunct Host-directed Immunotherapy for HIV-Tuberculosis |
| Funding Source: | NIH/NCI |
| Role: | Program Leader |
| ID: | AI138316 |
| Date: | 2017 - 2021 |
| Title: | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA201380 |
| Date: | 2017 - 2022 |
| Title: | BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA210250-01 |
| Date: | 2017 - 2022 |
| Title: | A Risk-Stratified Clinical Trial to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma Guided by a Molecular Signature and In Vivo Therapeutic Validation using Patient-Derived Xenograft Models |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA214624-01 |
| Date: | 2017 - 2019 |
| Title: | Identification of the distinct mutant RUNX1 gene-Expression Signature (RMES) in individuals with FPD/AML to identify mechanisms to inhibit or extinguish the aberrant RMES and prevent progression |
| Funding Source: | Alex's Lemonade Stand Foundation |
| Role: | Co-I |
| Date: | 2016 - 2019 |
| Title: | BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator-MDACC |
| ID: | IIRA |
| Date: | 2016 - 2017 |
| Title: | Leukemia SPORE Developmental Research Award |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | CA00632 |
| Date: | 2015 - 2016 |
| Title: | "BET Protein Bromodomain inhibotr-based therapy for Mantle Cell Lymphoma" |
| Funding Source: | MD Anderson Moonshot Program |
| Role: | Principal Investigator-MDACC |
| Date: | 2013 - 2014 |
| Title: | Spore in Lymphoma: Developmental Research |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | P50-CA126752 |
| Date: | 2013 - 2018 |
| Title: | Targeted Therapy for AML Stem Cells |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA173877 |
| Date: | 2013 - 2018 |
| Title: | Novel Targeted Therapy for AML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA171338 |
| Date: | 2008 - 2014 |
| Title: | Heat Shock Protein 90 Antagonist-Based Therapy of Mantle Cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA129962 |
| Date: | 2007 - 2014 |
| Title: | Histone Deacetylase Inhibitors Based Therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA123207 |
| Date: | 2005 - 2012 |
| Title: | Histone Deacetylase Inhibitors in CML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA116629 |
| Date: | 2005 - 2008 |
| Title: | Combinations of Novel Histone Deacetylase and Bcr-Abl Inhibitors in the Therapy of Imatinib Mesylate-Sensitive and Refractory Bcr-Abl Expressing Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-05-1-0211 |
| Date: | 2004 - 2009 |
| Title: | Targeting Apoptosis Signaling in Breast Cancer Cells |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA099999 |
| Date: | 2002 - 2005 |
| Title: | Control of Ara-C Induced Apoptosis of AML Cells |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA56613 |
| Date: | 2002 - 2007 |
| Title: | Gleevec Plus Novel Anti-Bcr-Abl Strategies in Leukemias |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA95188 |
| Date: | 2001 - 2004 |
| Title: | Arsenic-Based Therapy of Bcr-Abl Positive Leukemias |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA090717 |
| Date: | 1999 - 2004 |
| Title: | Role of PKR in Growth Regulation and Apoptosis |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01-CA72648 |
| Date: | 1998 - 2002 |
| Title: | Taxane-Induced Apoptosis: Regulation in Breast Cancer Cells |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA63382 |
| Date: | 1996 - 1998 |
| Title: | Activity of Paclitaxel Against Carcinoma of Esophagus |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21-CA73044 |
| Date: | 1994 - 1997 |
| Title: | Mechanism of Action and Resistance to Taxol in AML Cells |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA63382 |
| Date: | 1993 - 1996 |
| Title: | Antileukemic Selectivity of Ara-C Plus Hemopoietic Growth Factor |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA56613 |
Selected Publications
Peer-Reviewed Articles
- Bhalla KN, Bhalla K, Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Flores LB, Loghavi S, Su X, DiNardo CD, Bhalla KN. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood Cancer J 15:40, 2025. e-Pub 2025. PMID: 40089460.
- Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, Rodriguez-Meira A, Sui P, Olivier E, Jia Y, Gupta V, Fiskus W, Ramage CL, Zheng G, Schurer A, Gritsman K, Papapetrou EP, Bhalla KN, Zhou D, Mead AJ, Rampal RK, Tyner JW, Abbas HA, Pemmaraju N, Tatarata QZ, Konopleva MY. Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML. Blood, 2025. PMID: 40163809.
- Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29:4569-82, 2023. e-Pub 2023. PMID: 37585491.
- El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55:514-524, 2023. e-Pub 2023. PMID: 36933995.
- El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482:1011-1019, 2023. e-Pub 2023. PMID: 36864257.
- Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
- Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, Tang Z, Alswailmi O, Bhalla KN, Qazilbash MH, Konopleva M, Khoury JD. Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34884997.
- Soldi R, Halder TG, Sampson S, Vankayalapati H, Weston A, Thode T, Bhalla KN, Ng S, Rodriguez Del Villar R, Drenner K, Kaadige MR, Horrigan SK, Batra SK, Salgia R, Sharma S. The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein Complex. J Pharmacol Exp Ther 378(2):77-86, 2021. e-Pub 2021. PMID: 34006586.
- Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun 12(1):2607, 2021. e-Pub 2021. PMID: 33972549.
- Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
- Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34:1588-1598, 2020. e-Pub 2020. PMID: 31862959.
- Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
- DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G. Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes. J Immunol 201(1):124-133, 2018. e-Pub 2018. PMID: 29752313.
- DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401-407, 2018. e-Pub 2018. PMID: 29218851.
- Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia 32(1):49-60, 2018. e-Pub 2018. PMID: 28579617.
- Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Res Treat 165(2):375-382, 2017. e-Pub 2017. PMID: 28623430.
- Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
- Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica 102(3):519-528, 2017. e-Pub 2017. PMID: 27927766.
- Bhalla KN, Fiskus W. NEDD8 and HDACs: promising cotargets in AML. Blood 127(18):2168-70, 2016. e-Pub 2016. PMID: 27151736.
- Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy 33(12):1341-52, 2013. e-Pub 2013. PMID: 23798029.
- DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27(8):1628-36, 2013. e-Pub 2013. PMID: 23385375.
- Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19(13):3671-80, 2013. e-Pub 2013. PMID: 23757357.
- Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 27(4):907-13, 2013. e-Pub 2013. PMID: 23174881.
- Walker SL, Ariga J, Mathias JR, Coothankandaswamy V, Xie X, Distel M, Köster RW, Parsons MJ, Bhalla KN, Saxena MT, Mumm JS. Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafish. PLoS One 7(1):e29916, 2012. e-Pub 2012. PMID: 22238673.
- Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, Bhalla KN, Robertson KD. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet 20(1):126-40, 2011. e-Pub 2011. PMID: 20940144.
- Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141-5, 2011. e-Pub 2011. PMID: 21098399.
- Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy 6(1):19-35, 2010. e-Pub 2010. PMID: 20110775.
- Choi JH, Li Y, Guo J, Pei L, Rauch TA, Kramer RS, Macmil SL, Wiley GB, Bennett LB, Schnabel JL, Taylor KH, Kim S, Xu D, Sreekumar A, Pfeifer GP, Roe BA, Caldwell CW, Bhalla KN, Shi H. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS One 5(9), 2010. e-Pub 2010. PMID: 20927367.
- Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 15(12):1369-76, 2009. e-Pub 2009. PMID: 19966776.
- Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147(1):97-101, 2009. e-Pub 2009. PMID: 19663825.
- Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284(17):11171-83, 2009. e-Pub 2009. PMID: 19265193.
- Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 67(22):10744-52, 2007. e-Pub 2007. PMID: 18006817.
- Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66(13):6512-20, 2006. e-Pub 2006. PMID: 16818622.
- Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 69(5):1527-33, 2006. e-Pub 2006. PMID: 16436588.
- Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4(9):1311-9, 2005. e-Pub 2005. PMID: 16170022.
- Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65(2):613-21, 2005. e-Pub 2005. PMID: 15695406.
- Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 278(44):42992-3000, 2003. e-Pub 2003. PMID: 12933816.
- Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, Jove R, Wu J. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16(9):1589-95, 2002. e-Pub 2002. PMID: 12200668.
- Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. J Biol Chem 277(34):30622-8, 2002. e-Pub 2002. PMID: 12060665.
- Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 62(2):466-71, 2002. e-Pub 2002. PMID: 11809697.
- Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 15(10):1537-43, 2001. e-Pub 2001. PMID: 11587211.
- Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol 74(3):1513-23, 2000. e-Pub 2000. PMID: 10627563.
- Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 5(7):1723-30, 1999. e-Pub 1999. PMID: 10430075.
- Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80(3):337-44, 1993. e-Pub 1993. PMID: 8102493.
- Bhalla KN, Li GR, Grant S, Cole JT, MacLaughlin WW, Volsky DJ. The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine. AIDS 4(5):427-31, 1990. e-Pub 1990. PMID: 2115341.
Review Articles
- Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica 98(10):1499-509, 2013. e-Pub 2013. PMID: 24091929.
- Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23(17):3971-93, 2005. e-Pub 2005. PMID: 15897549.
- Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22(56):9075-86, 2003. e-Pub 2003. PMID: 14663486.
- O'Dwyer ME, La Rosée P, Nimmanapalli R, Bhalla KN, Druker BJ. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol 39(2 Suppl 1):18-21, 2002. e-Pub 2002. PMID: 12012318.
Abstracts
- Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM. Clinical and molecular characterization of p53-mutated acute myeloid leukemia. Blood 126(23):(#564), 2015. e-Pub 2015.
Book Chapters
- Bhalla K, Andreeff M. Nucleophosmin (NPM1). In: Targeted Therapy of Acute Myeloid Leukemia, 2014.
- Gerson SL, Bhalla KN, Grant S, Creger RJ, Bahlis NJ. Pharmacology and molecular mechanism of antineoplastic agents for hematologic malignancies. In: Hematology, Basic Principles and Practice. Churchill Livingston, 955-1017, 2005.
- Nimmanapalli R, Bhalla K. Targets in apoptosis signaling: Promise of selective anti-cancer therapy. In: Tumor Suppressor Genes: Methods and Protocols. Humana Press Inc, 465-483, 2002.
Patents
- Sphingolipid derivatives and their methods of use. Patent Number: 6,610,835.
- Histone deacetylase inhibitor enhancement of TRAIL-induced apoptosis. Patent Number: 7,786,170.
- Leukemia treatment method and composition. Patent Number: 7,732,476.
- Method of treating chronic myelogenous leukemia cells. Patent Number: 7,799,788.
Patient Reviews
CV information above last modified September 04, 2025